Review Article
Update on the Targeted Therapy of the Bladder Cancer
Omar Fahmy1 and Mohamed H Zahran2*
1Department of Urology, University Putra Malaysia, Malaysia
2Urology and Nephrology Center, Mansoura University, Egypt
*Corresponding author: Mohamed H. Zahran, Mansoura University, Urology and Nephrology Center, 35516, Egypt
Published: 19 Oct, 2016
Cite this article as: Fahmy O, Zahran MH. Update on the Targeted Therapy of the Bladder Cancer. Clin Oncol. 2016; 1: 1120.
Abstract
Bladder cancer was considered as immunogenic cancer many years ago since the detected response
to BCG instillation in the bladder. Recently, utilization of check point inhibitors in malignancies
is the new era in cancer immunotherapy. This novel treatment is now approved for melanomas,
however in bladder cancer still in the starting phase with promising results. Many trials have been
started to investigate the role of check point inhibitors in non-muscle invasive and in metastatic
bladder cancer. Many efforts at the pre-clinical level suggested a role for steroid hormones in bladder
cancer pathogenesis, however no available prospective data on the role of hormonal therapy in
bladder cancer. In this short review we present the updates on checkpoint inhibitors in the bladder
cancer and the suggested role for hormonal therapy in the future.
Keywords: Bladder cancer; Checkpoint inhibitors; Atezolizumab; Hormonal therapy; CTLA-4
Introduction
Bladder cancer (BC) is one of the aggressive tumors worldwide, and represents the 4th cause of cancer mortality in USA [1]. About 75% of patients present with non-muscle invasive disease (NMIBC) [2]. For these patients, transurethral resection of the bladder tumor is the main used treatment [3]. The other 25% of the patients have muscle invasive disease (MIBC) at the time of the first diagnosis [2]. Generally, the survival outcomes after treatment of BC are not satisfying. Indeed,
no improvement regarding the outcomes could be achieved in the last decades [3]. Up to 60% of
NMIBC patients may develop recurrence after been cured from BC [4]. For MIBC, in which Radical
Cystectomy (RC) is still the gold standard treatment, the overall survival after this operation is 50%
[5].
Currently, the ability of the malignant cells to evade the destruction by the immune system
is one of the cancer hallmarks [6]. Previously, BC immune-reactivity was early established after
introduction of Bacille-Calmette–Guerin (BCG) in the treatment of BC [7]. Immunotherapy
using Check Point Inhibitors (CPI) is now a new era in cancer treatment. After approval of CPI
in melanomas [8], trials were expanded to other malignancies, with promising initial results in
urological tumors [9,10].
BC displayed higher incidence in males than in females regardless the exposure to the risk
factors [11-13]. Furthermore, females displayed worse outcome than males based only on gender
difference [14]. Based on this gender related difference, hormonal characteristics of the BC have
been investigated and displayed some evidence of androgen and estrogen roles in BC pathogenesis
[15]. In this manuscript, we provide an updated overview on the targeted therapy of the BC and the
possibility to improve the current unpleasant outcome.
Immunotherapy
Normally immune system is under control of stimulatory and inhibitory signals to avoid
autoimmune destructive activity [16]. Inhibition of these inhibitory signals to maximize the
anti-tumor T-cell mediated immunity is the most recent strategy has been utilized in cancer
immunotherapy [17]. Two types of CPI are in current use to inhibit the inhibitory signals of
immune system.
Anti-PD-1/PD-L1
Programmed Death-1(PD-1) is widely expressed on immune cells including T- cells and Natural
Killer cells (NK). The main role of PD-1 is to limit the activity of immune system in the peripheral
tissues [18]. Expression of PD-1 in urothelial cancer cells detected by immunohistochemistry and
association with aggressive nature of BC was approved by some investigators [19]. This represented
the rationale to investigate the inhibition of PD-1 at the clinical level in BC patients. Trials on PD-1 inhibition in BC already started with promising preliminary results
[20]. Based on the available literature, the most promising results
for CPI in urothelial carcinoma were displayed by Atezolizumab
(MPDL3280A). This drug was investigated in about 150 patients
with metastatic BC [10]. Some correlation was detected between the
PD-1 positivity on the tumor infiltrating leucocytes and the response
rate. Furthermore, the overall response rate was significantly higher
in patients with non-visceral metastasis in comparison to patients
with visceral metastasis [10]. These initial results, however limited by
small number of participants, suggest the affection of response by the
metastatic burden. This also might be explained by better immune
reactivity in patients with less tumor burden as CPI itself not improve
the immune status directly, but only open the way to immune system
to attack the malignant cells.
One of the challenges in CPI application is the identification of
suitable patients who might get benefits from these expensive drugs.
Factors that can affect immune status might affect the response to
CPI; for example previous chemotherapy or radiotherapy. Clear
understanding of the impact of these therapeutic modalities on the
immune system is mandatory to optimize the usage of CPI in BC.
Also a very recent study reported on genomic based response to CPI
[21].
Anti-PD-1 displayed well tolerability. Fatigue and nausea were
the main reported side effects for these drugs [22].
Anti-CTLA-4
Anti T-lymphocyte-associated antigen 4 (CTLA-4) is the other
subgroup of CPI. NormallyCTLA-4 can down regulate the immune
activity through binding to B7 membrane protein of the antigen
presenting cell (APC) [23]. This type of CPI is already investigated
in prostate cancer [24]. Yet regarding BC, no clinical results were
reported until now. Only it was tested for tolerability in localized BC
patients by giving 2 doses before undergoing radical cystectomy [25]
and displayed acceptable tolerability, however less than anti PD-1.
Theoretically, this type of CPI was expected to improve the response
of non-muscle invasive bladder cancer to BCG [26]. Indeed, a Phase I
safety and efficacy clinical trial was launched to investigate the impact
of combination of BCG instillation with MK-3475 in non-muscle
invasive high risk BC (clinical trial NCT02324582).
Hormonal therapy
Is bladder cancer an endocrine sensitive tumor?
Until now, hormonal therapy has no role in the BC treatment,
however it is expected to investigated in the near future. Gender
disparity in bladder cancer is clinically evident. Number of men
diagnosed for BC is three to four times than affected females [27].
This was explained previously as smoking is more common in men
than women. This difference between genders was detected also in
smokers [28], which means that difference in exposure to smoking
cannot explain this gender disparity. Despite lower incidence, women
are presented with higher MIBC stages and have higher mortality
than men [29,30]. This might suggest higher progression of BC in
women. These clinical observations raised the question about the
role of androgen and estrogens in the pathogenesis of BC [15]. A
very recent meta-analysis on the Incidental Prostatic Cancer (IPC) in
radical cystoprostatectomy specimens suggested that IPC is might be
associated with more aggressive BC [31]. This might be explained on
basis of androgen sensitivity may be enrolled in the pathogenesis of
both prostatic and bladder cancers.
Clinical evidence on the role of hormonal therapy in BC
In a retrospective multi-center study, from 20328 BC patients 239
patients received Androgen Deprivation Therapy (ADT) for prostate
cancer. These subgroup displayed significant lower recurrence rate
of their BC than other patients (40% versus 76%, p <0.001) [32].
Tamoxifen was tested as a chemo-sensitizer in 30 patients with
advanced BC with reported response rate of 58% [33].
Conclusion
Checkpoint inhibitors are suggested to have a role in treatment of bladder cancer. Proper selection of the candidate patients for this kind of treatment still the main challenge. Complete understanding of the genomic criteria of bladder cancer and the impact of chemotherapy and radiotherapy on immune system can help optimal application of checkpoint inhibitors. Hormonal therapy might have a role in the near future; however the endocrinal basis of bladder cancer still not completely clarified.
References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30.
- Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P. et al. Epidemiology and risk factors of urothelialbladder cancer. Eur Urol. 2013; 63: 234-241.
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscleinvasiveurothelial carcinoma of the bladder: Update 2013. Eur Urol. 2013; 64: 639-653.
- Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive andmetastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014; 65: 778–792.
- EAU MIBC guidelines.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the nextgeneration. Cell. 2011; 144: 646–674.
- Bohle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology. 2004; 63: 682–686.
- Hodi FS, O’Day SJ, McDermott DF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–723.
- Carosella ED, Ploussard G, LeMaoult J, DesgrandchampsF. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, andHLA-G. Eur Urol. 2015; 68: 267–279.
- Fahmy O, Khairul-Asri M.G, Stenzl A, Gakis G. The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis. 2016.
- Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, et al. Genderandsmoking-related bladder cancer risk. J Natl Cancer Inst. 2001; 93: 538-545.
- Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, et al. Unexplained excess riskof bladder cancer in men. J Natl Cancer Inst. 1990; 82: 1636-1640.
- Scelo G, Brennan P. The epidemiology of bladder andkidney cancer. Nat Clin Pract Urol. 2007; 4: 205-217.
- Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, et al. Gender differencesin stage-adjusted bladder cancer survival. Urology. 2000; 55: 876-880.
- Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bl Cancer. 2016; 2: 127-137.
- Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015; 16: 343-353.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252–264.
- Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192: 1027–1031.
- Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PDL1 (B7-H1) expression byurothelial carcinoma of the bladder and BCGinduced granulomata: associations with localized stage progression. Cancer. 2007; 109: 1499–1505.
- Petrylak D, Powel T, Bellmunt J, Braiteh F, Loriot Y, ZambranoC, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol. 2015; 4501.
- Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016.
- Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515: 558–562.
- Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic Tlymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998; 188: 205–210.
- Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24: 1813–18121.
- Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability andimmune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010; 16: 2861–2871.
- Fahmy O, Khairul-Asri M.G, Stenzl A, Gakis G. Systemic anti-CTLA-4 and intravesical Bacille–Calmette–Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism? Med Hypotheses. 2016; 92: 57-58.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
- Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, et al. Gender and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001; 93: 538-545.
- Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000; 55: 876-880.
- Najari BB, Rink M, Li PS, Karakiewicz PI, Scherr DS, ShabsighR, Meryn S, Schlegel PN, Shariat SF. Sex disparities in cancer mortality: The risks of being a man in the United States. J Urol. 2013; 189: 1470-1474.
- Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G. Clinico-pathological features and prognostic value of incidental prostatic adenocarcinoma in radical cysto-prostatectomy specimens: a systematic review and meta-analysis of 13140 patients. J Urol. 2016.
- Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, et al. Androgen deprivation therapy prevents bladdercancer recurrence. Oncotarget. 2014; 5: 12665-12674.
- Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS. Combinationchemotherapy of cisplatin, methotrexate, vinblastine,and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001; 21: 711-715.